In Europe, Insulin Degludec to Cost 60-70% More Than LantusIn Europe, Insulin Degludec to Cost 60-70% More Than Lantus

Denmark's Novo Nordisk, the world's biggest insulin producer, will sell its long-acting insulin degludec (Tresiba) in Europe at a 60-70% premium over rival product Lantus from France's Sanofi. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news